Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Fig. 1

Flow cytometric analysis of D2C7 mAb and cytotoxicity of D2C7-IT against malignant glioma cell lines. a and c CT-2A-dmEGFRvIII-Luc (a) and SMA560-dmEGFRvIII-Luc (c) cell lines were stained with D2C7-AF488/−APC (pink open peaks) or IgG1-AF488/−APC isotype control Ab (filled purple peaks). b and d Cytotoxicity of D2C7-IT against CT-2A-dmEGFRvIII-Luc (b) and SMA560-dmEGFRvIII-Luc (d) cell lines was assessed by the WST-1 assay. The data are given as IC50 values, the concentration of D2C7-IT that causes 50% tumor cell death after a 48-h incubation

Back to article page